How does the 10,000-share option for STRO director Jagpal Sukhi vest?

The option vests as to 8.33% of the total award monthly, beginning on July 5, 2026. It becomes fully vested and exercisable on the earlier of Sutro Biopharma’s 2027 annual stockholders meeting or June 5, 2027, assuming ongoing service.

Sutro Biopharma (STRO) director receives 10,000-share stock option grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sutro Biopharma director Jagpal Sukhi received a new stock option grant for 10,000 shares of common stock. The option has an exercise price of $26.09 per share and expires on June 5, 2036. This is a compensation-related award rather than an open-market trade.

The option vests over time, with 8.33% of the total award vesting monthly, starting on July 5, 2026. The grant will be fully vested and exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 5, 2027, assuming continued service. After this grant, Sukhi holds options to acquire 10,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jagpal Sukhi

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 10,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 10,000 shares Exercise price: $26.09 per share Post-grant option holdings: 10,000 options +4 more

7 metrics

Option grant size 10,000 shares Stock option award to director Jagpal Sukhi

Exercise price $26.09 per share Stock option strike price

Post-grant option holdings 10,000 options Total derivative securities following transaction

Vesting rate 8.33% monthly Monthly vesting of total option award

Vesting start date July 5, 2026 First vesting tranche date

Full vesting date Earlier of 2027 meeting or June 5, 2027 Award fully vested and exercisable

Option expiration June 5, 2036 Option term end date

Key Terms

Stock Option (right to buy), exercise price, vesting date, annual stockholders meeting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 26.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting date financial

"shall vest ... on each vesting date, as to 8.33% of the total award monthly"

annual stockholders meeting regulatory

"the issuer's 2027 annual stockholders meeting"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/09/2026 - 04:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jagpal Sukhi

(Last)

(First)

(Middle)

C/O SUTRO BIOPHARMA, INC.

111 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUTRO BIOPHARMA, INC. [ STRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$26.09	06/05/2026		A		10,000		⁽¹⁾	06/05/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027.

	/s/ David Pauling as attorney-in-fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Sutro Biopharma (STRO) director Jagpal Sukhi report on this Form 4?

Director Jagpal Sukhi reported receiving a stock option grant for 10,000 shares of Sutro Biopharma common stock. The award is a compensation-related option, not an open-market purchase or sale, and establishes potential future ownership at a fixed exercise price.

What are the key terms of Jagpal Sukhi’s stock option grant at Sutro Biopharma (STRO)?

The option covers 10,000 shares of common stock at an exercise price of $26.09 per share and expires on June 5, 2036. It represents a right to buy shares in the future, subject to vesting conditions and continued service with the company.

Is Jagpal Sukhi’s Form 4 for STRO an open-market stock purchase or sale?

No, the Form 4 reports a grant of stock options, not an open-market trade. The transaction code “A” reflects a grant or award, giving Sukhi the right to buy 10,000 shares at $26.09 per share if and when the options vest.

How many STRO shares can Jagpal Sukhi acquire from this option grant?

The option grant allows Jagpal Sukhi to acquire 10,000 shares of Sutro Biopharma common stock upon exercise. These shares become exercisable over time as the award vests, and the option remains outstanding until its expiration in 2036 unless exercised earlier.